AEG vs MET: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: MET is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AEG and MET share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AEG and MET exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Aegon Ltd is a life insurance and retirement group whose center of gravity has shifted almost entirely to the United States. The dominant business is Transamerica, which sells individual life insurance, annuities, workplace retirement plans and mutual funds, and distributes much of that through World Financial Group, an agent network that passed 95,000 licensed agents during 2025. Outside the US, the group runs a UK workplace pensions and adviser platform, a joint venture with Santander across Spain and Portugal, an interest in Mongeral Aegon in Brazil, and an asset management arm. The company sold its Dutch insurance operations to a.s.r. in 2023 and has been steadily simplifying what remains. Roughly 15,300 people work there, and the reporting currency is still the euro even though the earnings are overwhelmingly dollar-denominated.

Full AEG guide

MetLife, Inc. is one of the world's largest providers of life insurance, employee benefits, annuities, and asset management, serving individuals and institutional clients across the United States, Asia, Latin America, Europe, the Middle East, and Africa. It reports through several segments, including Group Benefits (group life, dental, disability, and other workplace coverage), Retirement and Income Solutions (annuities, pension risk transfers, structured settlements, and stable value products), Asia, Latin America, EMEA, and MetLife Holdings, its book of legacy US business. The core model is classic insurance: collect premiums, pay claims and benefits over time, and invest the difference (the float) in a large fixed-income-heavy portfolio, earning a spread. That makes MetLife both an underwriter and a giant investor, so its profitability depends on disciplined pricing, mortality and morbidity trends, and the returns it earns on invested assets.

Full MET guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AEG drivers: Becoming an American company on paper, not just in practice; Capital generation drives a mechanical return of cash.
• MET drivers: Group Benefits and workplace demand; Retirement and Income Solutions.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The legacy American book is the reason the multiple is low: Transamerica carries long-term care and older universal life liabilities whose reserve adequacy depends on morbidity, mortality, lapse and claim-cost assumptions that get revisited annually, and an adverse review can wipe out a year of earnings growth in one press release. For MET, metLife's biggest risks come from the same levers that drive its profits.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AEG if you believe its drivers more; MET if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AEG and MET guides.

AEG. Aegon reports in euros on a half-yearly calendar, so the trailing US-dollar figures above are converted and will not line up exactly with the company's own releases. The most recent full set is the second-half and full-year 2025 report published February 19, 2026, which showed an operating result of about EUR 1.7 billion (up 15 percent) and a net result of about EUR 980 million (up 45 percent). First-half 2026 results are scheduled for August 20, 2026, and the numbers above sit ahead of that print.

MET. These are qualitative and approximate as of the asOf date and not precise real-time figures. Insurer results are heavily affected by interest rates, credit markets, and actuarial assumption changes, so reported numbers can differ sharply from adjusted ones. Confirm live revenue, EPS, dividend, and valuation before acting.

Headline figures (approximate, August 2026): AEG shows share price / market cap ~$9.45, ~$14.2 billion on ~1.51 billion shares, revenue (ttm) ~$14.3 billion, net income (ttm) ~$1.08 billion, EPS ~$0.69, p/e ~13x trailing, ~9.5x forward; MET shows revenue trend Full-year 2025 revenue was about $77.1 billion, up mid-single digits year over year; Q1 2026 revenue was roughly $19 billion, profitability Adjusted EPS has been rising (Q1 2026 adjusted EPS ~$2.42, up ~23% year over year), while reported net income can swing on investment and actuarial items, balance sheet / leverage Large, mostly fixed-income investment portfolio backing long-duration liabilities; capital-intensive and regulated, with statutory capital and ratings constraints, capital returns Raised the quarterly dividend ~4.4% to $0.5925 per share in 2026 and extended buybacks; targets $25 billion-plus of free cash flow over its plan.

AEG and MET are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AEG and MET exposure against your real portfolio. It is not an investment adviser.